Search Results
Individualizing Treatment With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
Applying Guidelines and Evidence to Individualize T2DM Treatment With GLP-1 RAs
Using GLP-1 RAs to Individualize Therapy in T2DM
The use of GLP-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients
Reducing Cardiometabolic Risks and Achieving Glycemic Targets With GLP-1 RAs
Partnering With Peers and Patients: Achieving T2DM Treatment Goals With GLP-1 RA Therapy
Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity
Multidisciplinary insights on role of GLP-1 RAs in modern management of stroke in patients with T2D
GLP 1 RAs Real World Patient Care Strategies for Type 2
Using GLP-1 Agonists in Patients With T2D and CVD
Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'
GLP-1 RA Therapy in T2D - Vinni Makin, MD, Kevin M. Pantalone, DO, Pratibha PR Rao, MD, MPH
